| 27.56 0.16 (0.58%) | 08-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 33.42 | 1-year : | 39.04 |
| Resists | First : | 28.62 | Second : | 33.42 |
| Pivot price | 25.46  |
|||
| Supports | First : | 24.27 | Second : | 21.59 |
| MAs | MA(5) : | 27.31 |
MA(20) : | 24.73 |
| MA(100) : | 22.25 |
MA(250) : | 19.65 |
|
| MACD | MACD : | 1.3 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 81 |
D(3) : | 79.6  |
| RSI | RSI(14): 67.8 |
|||
| 52-week | High : | 28.62 | Low : | 8.66 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IMNM ] has closed below upper band by 19.4%. Bollinger Bands are 63.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 27.72 - 27.83 | 27.83 - 27.94 |
| Low: | 26.56 - 26.68 | 26.68 - 26.81 |
| Close: | 27.35 - 27.55 | 27.55 - 27.75 |
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Wed, 19 Aug 2026
Immunome (IMNM) Faces A Valuation Test Following Earnings And Shelf Registration - sahmcapital.com
Tue, 18 Aug 2026
Immunome, Inc. (NASDAQ:IMNM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Sun, 16 Aug 2026
Immunome director Isaac Barchas sells $940,453 in common stock - Investing.com
Sun, 16 Aug 2026
Dimensional Fund Advisors LP Decreases Stock Position in Immunome, Inc. $IMNM - MarketBeat
Sat, 15 Aug 2026
Immunome (IMNM) Is Up 8.7% After Wider Loss And ESOP Shelf Filing What’s Changed - simplywall.st
Fri, 14 Aug 2026
T. Rowe Price Investment Management (IMNM) discloses 17.4% Immunome ownership, key fund at 6.5% - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 113 (M) |
| Held by Insiders | 1.0831e+008 (%) |
| Held by Institutions | 6.6 (%) |
| Shares Short | 18,150 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.2635e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 698.8 % |
| Return on Equity (ttm) | -29.8 % |
| Qtrly Rev. Growth | 4.01e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -23.66 |
| EBITDA (p.s.) | -8.6217e+007 |
| Qtrly Earnings Growth | -2.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -197 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.17 |
| Price to Cash Flow | 11.23 |
| Dividend | 0 |
| Forward Dividend | 1.724e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|